Depression and brief periods of manic symptoms are linked to a significant risk of progression to bipolar disorder (BD) in children who have a first-degree relative with BD I or II. However, little evidence exists to guide the pharmacologic management of children with these high-risk phenotypes. We propose a pharmacological treatment algorithm for high-risk youth and present results on its use in a study of children with a first-degree relative with BD.
Methods:
Subjects were 40 youth (mean 12.7 years, range 9–17 years) who had (1) a first-degree relative with lifetime history of BD I or II, (2) DSM-IV-TR diagnoses of BD not otherwise specified, major depressive disorder or cyclothymic disorder, and (3) active symptoms of depression, mania, or hypomania. Participants and their families were enrolled in a randomized trial examining the effects of two psychosocial interventions on the 1-year course of mood disorder. At study intake, participants received a psychiatric evaluation and were offered medications or had existing medications optimized to decrease symptom severity. During the 1-year study, psychiatrists treated participants using a medication algorithm to treat depressive or manic symptoms as well as comorbid anxiety and/or attention-deficit/hyperactivity disorder.
Results:
At study entry, 25 of 40 (62.5%) of the participants were taking at least one psychiatric medication. At 1 year, nearly an identical proportion were taking medications (22 of 35, 63%). Independent ratings indicated that in 84.7% of the study visits, physicians maintained adherence to the algorithm. No patients experienced antidepressant- or stimulant-induced mania during the study.
Conclusions:
An algorithmic approach to pharmacologic interventions may aid in the management of youth (i.e., age <18) at high risk for BD. Future studies should compare outcomes in high-risk patients receiving algorithm-prescribed treatment versus those receiving treatment as usual.
Clinical Trial Registration Information: Early Family-Focused Treatment for Youth at Risk for Bipolar Disorder; www.clinicaltrials.gov/; NCT00943085.
Get full access to this article
View all access options for this article.
References
1.
American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry, 46:267–283, 2007a.
2.
American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 46:894–921, 2007b.
3.
American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry, 46:1503–1526, 2007c.
4.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
5.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
6.
AxelsonD, BirmaherB, StroberM, GillMK, ValeriS, ChiappettaL, RyanN, LeonardH, HuntJ, IyengarS, BridgeJ, KellerM: Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry, 63:1139–1148, 2006.
7.
BirmaherB, AxelsonD, GoldsteinB, StroberM, GillMK, HuntJ, HouckP, HaW, LyengarS, KimE, YenS: Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: The Course and Outcome of Bipolar Youth (COBY) study. Am J Psychiatry, 166:795–804, 2009.
8.
ChangK, SaxenaK, HoweM: An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry, 45:298–304, 2006.
9.
ChangKD, DienesK, BlaseyC, AdlemanN, KetterT, SteinerH: Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J Clin Psychiatry, 64:936–942, 2003.
10.
CheungAH, EmslieGJ, MayesTL: Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry, 46:735–754, 2005.
11.
DelBelloMP, AdlerCM, WhitselRM, StanfordKE, StrakowskiSM: A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry, 68:789–795, 2007.
12.
DelBelloMP, ChangK, WelgeJA, AdlerCM, RanaM, HoweM, BryanH, VogelD, SampangS, DelgadoSV, SorterM, StrakowskiSM: A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord, 11:483–493, 2009.
13.
DelBelloMP, SoutulloCA, HendricksW, NiemeierRT, McElroySL, StrakowskiSM: Prior stimulant treatment in adolescents with bipolar disorder: Association with age at onset. Bipolar Disord, 3:53–57, 2001.
14.
FiedorowiczJG, EndicottJ, LeonAC, SolomonDA, KellerMB, CoryellWH: Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry, 168:40–48, 2011.
15.
FindlingRL, FrazierTW, YoungstromEA, McNamaraNK, StansbreyRJ, GraciousBL, ReedMD, DemeterCA, CalabreseJR: Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J Clin Psychiatry, 68:781–788, 2007.
16.
FindlingRL, LinglerJ, RowlesBM, McNamaraNK, CalabreseJR: A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. J Child Adolesc Psychopharmacol, 18:615–621, 2008.
17.
GellerB, CooperTB, ZimermanB, FrazierJ, WilliamsM, HeathJ, WarnerK: Lithium for prepubertal depressed children with family history predictors of future bipolarity: A double-blind, placebo-controlled study. J Affect Disord, 51:165–175, 1998.
18.
GellerB, ZimermanB, WilliamsM, BolhofnerK, CraneyJL, DelBelloMP, SoutulloC: Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. J Am Acad Child Adolesc Psychiatry, 40:450–455, 2001.
19.
GellerB, CraneyJL, BolhofnerK, NickelsburgMJ, WilliamsM, ZimermanB: Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry, 159:927–933, 2002.
20.
GlodCA, LynchA, FlynnE, BerkowitzC, BaldessariniRJ: Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 16:123–130, 2003.
21.
GoldbergJF, BrooksJO3rd, KuritaK, HoblynJC, GhaemiSN, PerlisRH, MiklowitzDJ, KetterTA, SachsGS, ThaseME: Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: Findings from the STEP-BD. J Clin Psychiatry, 70:155–162, 2009.
22.
GoldsmithM, SinghM, ChangK: Antidepressants and psychostimulants in pediatric populations: Isthere an association with mania?. Paediatr Drugs, 13:225–243, 2011.
23.
GrofP, DuffyA, CavazzoniP, GrofE, GarnhamJ, MacDougallM, O'DonovanC, AldaM: Is response to prophylactic lithium a familial trait?. J Clin Psychiatry, 63:942–947, 2002.
24.
HafemanDM, MerrankoJ, AxelsonD, GoldsteinBI, GoldsteinT, MonkK, HickeyMB, SakolskyD, DilerR, LyengarS, BrentD, KupferK, BirmaherB: Toward the definition of a bipolar prodrome: Dimensional predictors of bipolar spectrum disorders in at-risk youths. Am J Psychiatry, 173:695–704, 2016.
25.
KatonW, Von KorffM, LinE, WalkerE, SimonGE, BushT, RobinsonP, RussoJ: Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA, 273:1026–1031, 1995.
26.
KellerMB, LavoriPW, FriedmanB, NielsenE, EndicottJ, McDonald-ScottP, AndreasenNC: The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry, 44:540–548, 1987.
27.
KowatchRA, FristadM, BirmaherB, WagnerKD, FindlingRL, HellanderM; Child Psychiatric Workdgroup on Bipolar Disorders. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry, 44:213–235, 2005.
28.
MiklowitzDJ, ChangKD, TaylorDO, GeorgeEL, SinghMK, SchneckCD, DickinsonLM, HoweME, GarberJ: Early psychosocial intervention for youth at risk for bipolar I or II disorder: A one-year treatment development trial. Bipolar Disord, 13:67–75, 2011.
29.
MiklowitzDJ, SchneckCD, GeorgeEL, TaylorDO, SugarCA, BirmaherB, KowatchRA, DelBelloMP, AxelsonDA: Pharmacotherapy and family-focused treatment for adolescents with bipolar I and II disorders: A 2-year randomized trial. Am J Psychiatry, 171:658–667, 2014.
30.
MiklowitzDJ, SchneckCD, SinghMK, TaylorDO, GeorgeEL, CosgroveVE, HoweME, DickinsonLM, GarberJ, ChangKD: Early intervention for symptomatic youth at risk for bipolar disorder: A randomized trial of family-focused therapy. J Am Acad Child Adolesc Psychiatry, 52:121–131, 2013.
PandeAC, PollackMH, CrockattJ, GreinerM, ChouinardG, LydiardRB, TaylorCB, DagerSR, ShiovitzT: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol, 20:467–471, 2000.
33.
PatelNC, DelBelloMP, BryanHS, AdlerCM, KowatchRA, StanfordK, StrakowskiSM: Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry, 45:289–297, 2006.
34.
PavuluriMN, HenryDB, MossM, MohammedT, CarbrayJA, SweeneyJA: Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J Child Adolesc Psychopharmacol, 19:75–82, 2009.
35.
PostRM, LeverichGS, KupkaRW, KeckPE, AltshulerLL, FryeMA, LuckenbaughtDA, RoweM, GrunzeH, SuppesT, NolenWA: Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry, 71:864–872, 2010.
36.
PoznanskiEO, MokrosHB: Children's Depression Rating Scale, Revised (CDRS-R) Manual. Los Angeles, CA, Western Psychological Services, 1995.
37.
SheehanDV, LecrubierY, SheehanKH, AmorimP, JanavsJ, WeillerE, HerguetaT, BakerR, DunbarGC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 59Suppl 20:22–33, 1998.
38.
Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128:1007–1022, 2011.
39.
TramontinaS, ZeniCP, KetzerCR, PheulaGF, NarvaezJ, RohdeLA: Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: A pilot randomized clinical trial. J Clin Psychiatry, 70:756–764, 2006.
40.
UrbanoMR, SpiegelDR, LaguertaN, ShraderCJ, RoweDF, HateganLF: Gabapentin and tiagabine for social anxiety: A randomized, double-blind, crossover study of 8 adults. Prim Care Companion J Clin Psychiatry, 11:123, 2009.
41.
Van MeterAR, BurkeC, YoungstromEA, FaeddaGL, CorrellCU: The bipolar prodrome: Meta-analysis of symptom prevalence prior to initial or recurrent mood episodes. J Am Acad Child Adolesc Psychiatry, 55:543–555, 2016.
42.
Van MeterAR, MoreiraAL, YoungstromEA: Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry, 72:1250–1256, 2011.
43.
YoungRC, BiggsJT, ZieglerVE, MeyerDA: A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry, 133:429–435, 1978.
